Patients who do not wish to participate in the study will be treated as usual.
Women who drop out of the study will be treated according to the local protocols and guidelines.
Patients who drop out of the study will be treated according to the local protocols and guidelines for subfertility patients.
Subjects withdrawn from the study will be treated according to the standard of care, including neurodevelopmental outcome assessment at the outpatient clinic.
Patients with a B12 deficiency also continuing in the comprehensive cohort study, will be treated with B12 injections as necessary by the GP.
Patients with folate deficiency continuing in the comprehensive cohort study will be treated with a 5 mg dose of folic acid.
The patients in the current study will be treated long term with ETA and followed up yearly by wb-MRI and by x-rays every 2 years, which will allow this question to be addressed in more detail in the future.
Furthermore, as during this study patients will be treated with a TKI, which has an inhibiting effect on tumour angiogenesis and tumour perfusion, it can theoretically be hypothesised that during/after treatment lesions will be low vascularized and perfused.
We expect that the results of this study will be helpful in treating and predicting the prognosis of patients with extreme hyperbilirubinemia.
